FRAMINGHAM, Mass., Feb. 15 /PRNewswire-FirstCall/ -- StatSure Diagnostic Systems, Inc. is pleased to announce that its patented oral-fluid collection device was successfully used by the National Highway Traffic Safety Administration (NHTSA), for a pilot test program (DOT HS 810 704) titled: Pilot Test of New Roadside Methodology for Impaired Driving. The company anticipates that its collection device will be incorporated as part of the next National NHTSA Roadside Survey. D. Bruce Pattison, President of SSUR, stated, “We were delighted with the results of this important pilot study and remain convinced that the benefits of a high- quality, oral-fluid collector will lead to substantial growth of drug of abuse testing with saliva.” StatSure’s oral- fluid collection product was utilized in conjunction with Immunalysis Corporation’s Quantisal(TM) system for drugs of abuse testing. The complete report of this pilot test can be found at www.nhta.gov.
About StatSure
StatSure Diagnostic Systems, Inc. is engaged in the development, manufacture and marketing of rapid immunoassay tests for the detection of sexually transmitted and other infectious diseases; in addition, the Company has developed and is marketing a product line of patented, oral-fluid collection devices. The Company’s proprietary platforms provide significant customer benefits and competitive advantages as compared to similar products that are currently available. Improved accuracy, operator convenience, and reduced risk of infection from collecting and handling specimens, have been engineered into SDS products. All of the company’s diagnostic tests are based on the same easy-to-use technology platform, thus facilitating the development of future products. Certain of these products are sold in the United States as well as internationally to various distributors for use in clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations.
Please visit our website at http://www.StatSure.com
Forward-Looking Statements
Statements contained herein that are not historical facts are forward- looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the company and its management. Such statements reflect management’s current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company’s ability to obtain additional financing and the demand for the Company’s products. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company’s expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company’s success are more fully disclosed in the Company’s most recent public filings with the U.S. Securities and Exchange Commission (“SEC”).
For more information visit our website at http://www.StatSure.com.
StatSure Diagnostic Systems, Inc.
CONTACT: Media: Steve Peltzman, CEO, +1-508-872-2634
